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expression in the trophoblast of 8-OHdG, p53, p21, APE1, 
and IL-6. In placentas of cases affected by PE, HELLP, 
or IUGR, there was an increased expression of 8-OHdG, 
p53, APE1, and IL-6 compared to controls (only IL-8 was 
significantly decreased in cases). In both groups of pathol-
ogy between 22- and 34-week gestation and after 34-week 
gestation, APE1 levels were higher in the trophoblast of 
women affected by hypertensive disorders of pregnancy 
than women carrying an IUGR fetus. The cytoplasmic 
expression of 8-OHdG was increased in placentas in IUGR 
cases compared to PE or HELLP pregnancies. In cases 
after 34-week gestation, p21 was higher in SGA and IUGR 
than in controls and late PE. Moreover, p53 was increased 
after 34-week gestation in IUGR pregnancies. Placentas 
from pathological pregnancies had an altered expression of 
8-OHdG, p53, p21, APE1, IL-6, and IL-8. The alterations 
of intracellular pathways involving these elements may be 
the cause or the consequence of placental dysfunction, but 
in any case reflect an impaired placental function, possibly 
due to increased aging velocity in pathologic cases.
Keywords 8-OHdG · p53 · p21 · APE1/Ref-1 · IL-6 · IL-
8 · Placenta · Preeclampsia · IUGR
Abbreviations
8-OHdG  8-Hydroxy-2′-deoxy-guanosine
AP  Apurinic/apyrimidinic
APE1  APE1/Ref-1 (apurinic apyrimidinic endonucle-
ase redox effector factor-1)
BER  Base excision repair
BMI  Body mass index
DNA  Deoxyribonucleic acid
HELLP  Hemolysis, elevated liver enzymes, low platelet 
count
IL-6  Interleukin-6
Abstract To evaluate the expression of markers cor-
related with cellular senescence and DNA damage 
(8-hydroxy-2′-deoxy-guanosine (8-OHdG), p53, p21, 
APE1/Ref-1 (APE1), interleukin (IL-6 and IL-8) in pla-
centas from healthy and pathologic pregnancies. This ret-
rospective study considered a placental tissue micro-array 
containing 92 controls from different gestational ages 
and 158 pathological cases including preeclampsia (PE), 
HELLP syndrome (hemolysis, elevated liver enzymes, 
low platelet count), small for gestational age (SGA) 
fetuses, and intrauterine growth restriction (IUGR) occur-
ring at different gestational ages. In this study, we dem-
onstrated a significant influence of gestational age on the 
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IL-8  Interleukin-8
IUGR  Intrauterine growth restriction
mRNA  Messenger ribonucleic acid
PE  Preeclampsia
RNA  Ribonucleic acid
SASP  Senescence-associated secretory phenotype
SGA  Small for gestational age
Introduction
Cell senescence is part of the life cycle of all living organ-
isms. The placenta is no exception: It too is formed, grows, 
performs its multiple functions (e.g., endocrine regulation 
and nourishment of the fetus), and ages. Of course, it is clear 
to us that a placenta’s life cycle lasts the course of a preg-
nancy just as it is clear that the speed of aging varies from 
individual to individual. In the same way, some individuals 
age more quickly than others, so there are likely to be some 
placentas that show signs of aging faster than others.
Cell aging may lead to apoptosis, resulting in aging 
first of tissues and subsequently organs. The placenta is 
an organ that may be related to several diseases: preec-
lampsia (PE), HELLP syndrome (hemolysis, elevated liver 
enzymes, low platelet count), gestational hypertension 
(GH), intrauterine growth restriction (IUGR), and small for 
gestational age (SGA) fetus. In addition, recent studies sug-
gest that cell senescence may play a role in PE and IUGR 
(Biron-Shental et al. 2010; Kudo et al. 2000; Izutsu et al. 
1998; Davy et al. 2009).
Cellular senescence is the result of progressive DNA 
damage (Lombard et al. 2005) which is responsible for the 
development of the cell’s senescent phenotype and it is deter-
mined by intrinsic (or endogenous) or extrinsic (exogenous) 
causes. Among intrinsic factors, the reactive oxygen metabo-
lites are the most frequent cause of damage. We evaluated 
the tissue immunohistochemical expression of a marker 
that highlights the presence of oxidized DNA: 8-hydroxy-
2′-deoxy-guanosine (8-OHdG). DNA damage results in the 
activation of tumor suppressor genes such as p53, which, in 
turn, lead to apoptosis and cell senescence, resulting in the 
loss of proliferative capacity (Rossi et al. 2008).
The p53 protein is a central transcription factor in the 
DNA damage response cascade. The p53 protein has many 
functions including transcription regulation, mRNA trans-
lation inhibition, DNA exonuclease, and genomic dam-
age detection and repair (Ginsberg et al. 1991; Ewen and 
Miller 1996; Reed et al. 1995). Once activated, p53 exerts 
its function in different ways: stimulation of transcription 
of genes involved in apoptosis, thus activating the apoptotic 
cascade (Miyashita et al. 1995; Rossé et al. 1998) or activa-
tion of p21 transcription to arrest the cell in the G1 phase 
and repair the DNA damage (Ljungman 2000). Without 
p21, p53 cannot stop the cycle in G1, as has been observed 
in mouse embryonic fibroblasts with DNA damage due to 
ionizing radiation (Ju et al. 2007). In addition to p53, there 
are also other factors (growth factors, cytokines, or gluco-
corticoids) that positively regulate p21 levels.
Damage caused by oxidative stress, including changes 
to DNA and proteins, as well as the mechanisms of DNA 
repair, appears to play a key role in obstetrical pathologies 
of placental origin, including PE and IUGR (Vascotto et al. 
2007; Takagi et al. 2004; Kimura et al. 2013; Rossi et al. 
2013; Tamura et al. 2011). In this paper, we also focus our 
attention on the immunohistochemical expression of APE1/
Ref-1 (APE1). This is involved both in the base excision 
repair (BER) pathway of DNA lesions, acting as the major 
apurinic/apyrimidinic (AP) endonuclease, and in transcrip-
tional regulation of gene expression, where it functions as 
a redox co-activator of different transcription factors that 
could lead to increased interleukin (IL)-6 and IL-8 expres-
sion (Cesaratto et al. 2013; Thakur et al. 2015; Tell et al. 
2005). IL-6 and IL-8 are two important immune-modula-
tory cytokines that are part of the senescence-associated 
secretory phenotype (SASP) (Coppé et al. 2008). SASP 
components could regulate the extracellular environment 
through both autocrine and paracrine mechanisms and 
chemokine or inflammatory cytokine signals are crucial 
senescence regulators (Young and Narita 2009). In particu-
lar, IL-6 has a central role in maintaining and amplifying 
the pro-senescence activity (Young and Narita 2009). Fur-
thermore, APE1 also has a role in telomere maintenance 
that we saw to be involved in pregnancy diseases of placen-
tal origin (Madlener et al. 2013; Biron-Shental et al. 2010).
This study aims to evaluate the expression of certain 
proteins correlated with cellular senescence in placentas 
from both healthy and pathologic pregnancies. In particu-
lar, we studied expressions of the following: an oxidative 
stress damage marker to the DNA double strand, p53, p21, 
APE1, IL-6, and IL-8.
Materials and methods
Clinical information
This retrospective study was approved by the internal 
review board (IRB) and conducted in accordance with 
the Declaration of Helsinki. We considered the following 
pathologies: PE, HELLP, GH, SGA, and IUGR. PE, GH, 
and HELLP were based on previous definitions. Diagnosis 
of GH was defined as systolic blood pressure of 140 mmHg 
or more and diastolic blood pressure of 90 mmHg or more 
on two occasions after 20 weeks of gestation in a previ-
ously normotensive woman (Brown et al. 2001). PE was 
defined as the same as GH, but with proteinuria that was 
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considered as the urinary excretion of 0.3 g protein or 
greater in a 24-h period (this usually correlates with 30 mg/
dl or greater in a random urine determination) (Brown et al. 
2001). HELLP was defined as the presence of hemoly-
sis, cytolysis (elevated liver enzymes), and thrombocyto-
penia (platelets count <100,000) (Baxter and Weinstein 
2004; Fruscalzo et al. 2012). Similarly, IUGR (estimated 
fetal weight <10th centile and umbilical artery pulsatility 
index >2 standard deviations) and SGA fetuses (estimated 
fetal weight <10th centile with normal fetal Doppler) were 
based on previous definitions (Visentin et al. 2014). Gesta-
tional age at pregnancy term was based on last menstrual 
period with fetal dating confirmed by ultrasound in the first 
trimester of gestation. Furthermore, considered pathologies 
were stratified according to gestational age into those diag-
nosed before and those diagnosed after 34 complete week 
gestation. Other clinical information was gathered from the 
local clinical database and included the following: maternal 
age, pre-pregnancy body mass index (BMI), parity, mater-
nal race, fetal sex, and both neonatal and placental weight. 
We restricted our population to Caucasians and black Afri-
cans. Lastly, we calculated placental index by dividing pla-
cental weight in grams (placentas were weighed shortly 
after delivery with membranes and umbilical cord attached) 
by birth weight in grams (Londero et al. 2013).
Markers and patients selection
This study investigates the immunohistochemical expres-
sion of 8-OHdG, p53, p21, APE1, IL-6, and IL-8 in placen-
tal cytotrophoblast and syncytiotrophoblast. Our control set 
consisted of: 28 placentas from voluntary pregnancy inter-
ruption before the 12- or 22-week gestation; 13 placentas 
from voluntary pregnancy interruption for severe fetal mal-
formations at the University of Muenster between the 22- 
and 34-week gestation; and 51 placentas from deliveries 
found to have a normal pregnancy course. For pregnancy 
pathologies, our cases diagnosed before 34-week gesta-
tion comprised: 36 placentas from pregnancies affected by 
PE; 8 placentas from pregnancies affected by PE associ-
ated with IUGR; 17 placentas from pregnancies affected 
by IUGR; and 6 placentas from pregnancies affected by 
HELLP. Cases diagnosed after 34-week gestation com-
prised: 14 placentas from pregnancies affected by PE; 7 
placentas from pregnancies affected by PE associated with 
IUGR; 18 placentas from pregnancies affected by SGA; 
35 placentas from pregnancies affected by IUGR; 11 pla-
centas from pregnancies affected by GH; 6 placentas from 
pregnancies affected by GH and SGA. All placentas from 
pathologic pregnancies were identified from the registry of 
the Pathology Department of the Udine University for the 
period from January 2001 to December 2010. The pathol-
ogy set as a whole consisted of all available placentas from 
pregnancies diagnosed with the studied pathologies from 
the Pathology Institute of the University of Udine. Selec-
tion of the full-term delivery cases was on the basis of 
available placentas from the last 51 consecutively placed 
normal pregnancies from the Pathology Institute of the Uni-
versity of Udine; similarly, the selection for those before 12 
or 22 weeks was the last 28 consecutively placed voluntary 
pregnancy terminations before 12- or 22-week gestation (in 
respect to Italian laws), all as reported in the department 
register of Udine (Italy). Control cases before 34-week ges-
tation were the last 13 consecutively placed voluntary preg-
nancy terminations before 34-week gestation as reported 
in the department register of University of Muenster (Ger-
many). These 13 normally evolved pregnancies were termi-
nated in accordance with local law via medically induced 
abortion as a result of isolated fetal malformations (five 
Spina bifida, four hydrocephalus, and four cardiac com-
plex malformations) and were in part used for a previous 
study (Fruscalzo et al. 2012). All pregnancies in our sample 
were singleton. Clinical information was gathered from our 
clinical files. We excluded pregnancies with the following 
characteristics: those known to be complicated by infection 
or placenta abruptio, those carrying a vanishing twin, those 
resulting in early preterm labor and subsequent delivery, 
and those with chromosomal abnormalities. In the control 
group, we additionally excluded other pathologies (gesta-
tional diabetes, pre-gestational diabetes, colestasis).
Preparation of tissue micro‑array
Placental tissue blocks were fixed by formalin and included 
in paraffin. Sections were then stained by hematoxylin-
eosin (H&E), and carefully examined, excluding areas of 
placental infarction, before performing sampling for the tis-
sue micro-array. We consequently obtained two biopsies for 
each identified paraffin block. Tissue micro-array (TMA) 
was completed using a Beecher tissue micro-arrayer. A 
cylindrical, thin-walled needle (inner diameter of 1.5 mm) 
was used for coring tissues and for transferring cored sam-
ples into array cavities in the recipient block. From the 
recipient block, we obtained 4-µm-thick transverse sec-
tions, which were placed on a glass slide and stained. For 
this study, we used six sections and all samples proved ade-
quate for evaluation.
Analysis of tissue micro‑array
Sections were deparaffinated, rehydrated, and incubated 
with H2O2 for 10 min to block endogenous peroxidase 
activity. Antigen retrieval was performed in citrate buffer 
at pH6 (high pH in case of IL-6 and IL-8) and at a tem-
perature of 98 °C. The sections were rinsed in PBS and 
then incubated in a wet chamber at room temperature for 
 Histochem Cell Biol
1 3
60 min with the following antibodies: p53 (Dako, diluted 
1:100, monoclonal), p21 (Calbiochem, diluted 1:25, mon-
oclonal), 8-OHdG (JaICA, diluted 1:10, monoclonal), 
IL-6 (Abcam, AB6672, diluted 1:400, polyclonal), IL-8 
(Abcam, AB106350, diluted 1:250, polyclonal), and APE1 
(Novus, diluted 1:300, monochlonal) (Vascotto et al. 2009). 
A Dako REAL™ EnVision™ Dako Rabbit/Mouse (K5007, 
DakoCytomation, Glostrup, DK) was used as second anti-
body. HRP activity was detected using Dako REAL™ 
DAB + Chromogen (K5007, DakoCytomation, Glostrup, 
DK) as substrate for 3 min in accordance with the manu-
facturer’s instructions. Sections were counter stained with 
hematoxylin before mounting. To provide a negative con-
trol, we used the primary antibody without adding the 
secondary antibody, while a positive control was achieved 
by analyzing different tissue samples suggested by manu-
facturer. Two pathologists independently performed semi-
quantitative analysis of the immunohistochemical staining. 
Cytoplasm staining was evaluated by intensity score as 
strong 3, moderate 2, weak 1, and absent 0. Nuclear stain-
ing for APE1 and 8-OHdG was evaluated by H-score (the 
product of actual percentage of positive-stained nuclei and 
intensity score—evaluated as strong 3, moderate 2 and 
weak 1—giving a possible range of 0–300) while, as per 
the standard protocol of our Institute of Pathology, nuclear 
expression of p21 and p53 was evaluated as percentage of 
positive nuclei. In case of discordance, a joint assessment 
was performed by the two pathologists.
Statistical analysis
Data were analyzed using R version 3.0.1 with p < 0.05 
considered significant. T test, Wilcoxon test, Kruskal–Wallis 
test, Spearman test, Kendall test, Chi-square test, and Fisher 
exact tests were performed as appropriate. In addition, mul-
tivariate logistic regression analysis was performed, for 
which the expression of a marker over the median of its dis-
tribution was considered as the dependent variable.
Results
Population description
In Table 1, we report the general characteristics of the 
study population. Table 1A summarizes the characteristics 
of pathological and healthy pregnancies before 34-week 
gestation, where we note a significantly reduced placental 
weight in IUGR cases.
Table 1B reports the characteristics of pathological and 
healthy pregnancies after 34-week gestation. As expected, 
significant differences have been found for maternal age, 
BMI before pregnancy, gestational age at the end of preg-
nancy, neonatal weight, nulliparity, and race.
Immunohistochemical analysis of 8‑OHdG, p53, p21, 
APE1, IL‑6, and IL‑8 in the normal placenta
We observed p53 and p21 expressions only in the nucleus, 
IL-6 and IL-8 expressions only in the cytoplasm, and 
APE1 and 8-OHdG expressions in both the nucleus and 
the cytoplasm. Figure 1, taking into consideration only 
control placentas, shows the immunohistochemical 
expression of the studied proteins correlated with ges-
tational age. P21 was found to significantly decrease as 
gestational age increased. Looking solely at controls, p53 
and IL-6 levels seemed constant with increasing gesta-
tional age. As gestational age increased, so too did APE1 
and 8-OHdG immunohistochemical expressions into 
the nuclei, while in the cytoplasm only APE1 increased 
with gestational age, with 8-OHdG decreasing (p < 0.05) 
(Fig. 1). In addition, we found a non-significant increase 
of IL-6 and decrease of IL-8 with the increase in gesta-
tional age (Fig. 1g, h).
Although both p53 and p21 immunohistochemical 
scores showed a significant positive correlation (p < 0.05), 
the immunohistochemical score for p21 was higher than 
that of p53. In fact, Table 2 shows that in control placentas, 
both between 22- and 34-week gestation and after 34-week 
gestation, p21 expression was three to ten times higher than 
p53. Furthermore, if we took only controls, or both controls 
and cases together or stratified by gestational age, nuclear 
8-OHdG score was significantly and positively correlated 
with nuclear p53 and nuclear APE1 scores (p < 0.05). In 
addition, nuclear APE1 was positively correlated with cyto-
plasmic IL-6 score and nuclear p53 score (p < 0.05).
We then proceeded to assess whether correlations 
existed between the expression of the studied factors and 
the placental index. Interestingly, we discovered a sig-
nificant positive correlation between placental index and 
8-OHdG immunohistochemical score in control placentas 
(p < 0.05), while in pathological placentas the correlation 
with 8-OHdG lost its significance.
Immunohistochemical analysis of 8‑OHdG, p53, 
p21, APE1, IL‑6, and IL‑8 in pregnancy pathology 
before 34‑week gestation and in controls
Table 2A reports immunohistochemical expression of the 
studied proteins among the various pathology groups and 
controls with pregnancies terminated before 34-week ges-
tation, and from these data we can assess the differences 
between cases and controls. The most prominent differ-
ences are to be seen in the expressions of 8-OHdG, p53, 
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APE1, IL-6, and IL-8 (Tables 2A, 3). In fact, nuclear 
H-score of 8-OHdG, p53 positivity, cytoplasmatic inten-
sity of APE1, and IL-6 were all found to be higher in 
every pathology group than in controls (Fig. 2). Nuclear 
H-score of APE1 was significantly increased only in PE 
or HELLP cases when compared with controls (Fig. 2) 
and cytoplasmic intensity score of IL-8 was significantly 
decreased in every pathology group in comparison with 
controls (Table 3).
Looking at variations between the pathology groups in 
more depth, we observed that nuclear APE1 expression 
levels were higher in PE and HELLP pregnancies than 
Table 1  Description of the population: (A) cases and controls <34-week gestation; (B) cases and controls >34-week gestation
The values reported refer to mean ± standard deviation or percentage and absolute values, and p values refer to t test, Chi-square test of Fisher 
exact test
(A) Significant differences between: (1) early PE versus early PE and IUGR; (2) early PE versus early HELLP; (3) early PE versus early IUGR; 
(4) early PE versus controls 22–34-week gestation; (5) early PE and IUGR versus early HELLP; (6) early PE and IUGR versus early IUGR; (7) 
early PE and IUGR versus controls 22–34-week gestation; (8) early HELLP versus early IUGR; (9) early HELLP versus controls 22–34-week 
gestation; (10) early IUGR versus controls 22–34-week gestation. (Ns) = non-significant
(B) Significant differences between: (1) late PE versus late PE and IUGR; (2) late PE versus late IUGR; (3) late PE versus late SGA; (4) late PE 
versus controls 34–42-week gestation; (5) late PE and IUGR versus late IUGR; (6) late PE and IUGR versus late SGA; (7) late PE and IUGR 
versus controls 34–42-week gestation; (8) late IUGR versus Late SGA; (9) late IUGR versus controls 34–42-week gestation; (10) late SGA ver-
sus controls 34–42-week gestation. (NS) = non-significant
Number of pregnancies Early PE Early PE and IUGR Early HELLP Early IUGR Controls 22–34-week 
gestation
p
36 8 6 17 13
(A)
Mother age (years) 32.06 (±6.99) 33.50 (±5.26) 36.00 (±5.55) 32.71 (±5.7) 30.69 (±6.36) NS
Pre-pregnancy BMI (kg/
m2)
24.52 (±4.67) 23.17 (±3.49) 24.40 (±5.59) 21.92 (±3.43) 24.15 (±4.56) NS
Gestational age at delivery 
(weeks)
30.03 (±2.08) 31.00 (±2.56) 30.50 (±1.52) 28.94 (±3.73) 27.51 (±2.61) 4, 7 ,9
Neonatal weight (g) 1380.36 (±465.21) 1111.12 (±335.71) 1333.33 (±332.25) 975.71 (±336) 1086.54 (±629.85) 3
Placental weight (g) 356.00 (±127.81) 277.00 (±90.17) 370.83 (±114.91) 261.47 (±106.12) 276.25 (±99.91) 3, 4
Placental index 0.27 (±0.08) 0.25 (±0.03) 0.28 (±0.04) 0.27 (±0.05) 0.33 (±0.14) NS
Nulliparity 75 % (27/36) 88 % (7/8) 83 % (5/6) 65 % (11/17) 44 % (4/9) NS
Race
 Caucasian 94 % (33/35) 100 % (8/8) 83 % (5/6) 88 % (15/17) 100 % (13/13) NS
 African 6 % (2/35) 0 % (0/8) 17 % (1/6) 12 % (2/17) 0 % (0/13) NS
 Male sex 64 % (23/36) 75 % (6/8) 50 % (3/6) 59 % (10/17) 20 % (2/10) 4, 7, 10
Number of pregnan-
cies
Late PE Late PE and IUGR Late IUGR Late SGA Controls 34–42- 
week gestation
p
14 7 35 18 51
(B)
Mother age (years) 32.79 (±6.12) 36.71 (±6.07) 31.41 (±5.42) 33.89 (±4.91) 31.06 (±6.06) NS
Pre-pregnancy BMI 
(kg/m2)
25.62 (±7.15) 24.17 (±5.08) 22.03 (±3.88) 20.93 (±2.15) 22.63 (±4.52) 3
Gestational age at 
delivery (weeks)
37.13 (±1.93) 35.57 (±1.72) 37.79 (±1.79) 37.50 (±1.89) 38.00 (±2.01) 5, 6, 7
Neonatal weight (g) 2645.71 (±637.38) 1736.14 (±563.4) 2210.21 (±448.28) 2340.72 (± 436.71) 2954.48 (± 568.33) 1, 2, 6, 7, 9, 10
Placental weight (g) 524.62 (±150.46) 366.43 (±43.27) 410.76 (±63.17) 450.67 (± 93.92) 514.29 (± 124.37) 1, 2, 5, 6, 7, 9
Placental index 0.20 (±0.04) 0.23 (±0.06) 0.20 (±0.07) 0.20 (± 0.06) 0.19 (± 0.04) NS
Nulliparity 62 % (8/13) 43 % (3/7) 74 % (25/34) 89 % (16/18) 75 % (18/24) 6
Race
 Caucasian 86 % (12/14) 86 % (6/7) 91 % (31/34) 100 % (18/18) 98 % (45/46) NS
 African 14 % (2/14) 14 % (1/7) 9 % (3/34) 0 % (0/18) 2 % (1/46) NS
Male sex 43 % (6/14) 57 % (4/7) 65 % (22/34) 33 % (6/18) 52 % (22/42) 8
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Fig. 1  Correlation between gestational age and expression of stud-
ied proteins. a p21 nuclear positivity Spearman’s rho = −0.350 
(p < 0.05, Kendall’s p < 0.05). b p53 nuclear positivity Spearman’s 
rho = 0.056 (p = 0.477, Kendall’s p = 0.493). c: APE1 nuclear 
positivity Spearman’s rho = 0.418 (p < 0.05, Kendall’s p < 0.05). d 
8-OHdG nuclear positivity Spearman’s rho = 0.655 (p < 0.05, Ken-
dall’s p < 0.05). e APE1 cytoplasm intensity Spearman’s rho = 0.230 
(p < 0.05, Kendall’s p < 0.05). f 8-OHdG cytoplasm intensity Spear-
man’s rho = −0.322 (p < 0.05, Kendall’s p < 0.05). g IL-6 cytoplasm 
intensity Spearman’s rho = 0.099 (p = 0.267, Kendall’s p = 0.298). 
h IL-8 cytoplasm intensity Spearman’s rho = −0.102 (p = 0.215, 
Kendall’s p = 0.247)
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in IUGR pregnancies. Conversely, no significant differ-
ences existed when we looked at the nuclear expression 
of 8-OHdG, which generally was present at higher levels 
in pathological than in healthy placentas, yet cytoplasmic 
8-OHdG was expressed in higher levels in IUGR cases 
than in HELLP or PE (p = 0.071 and p < 0.05 selecting 
only HELLP). In Table 2, we found significant variations 
in cytoplasmic expression of APE1 without macroscopic 
differences among medians, and as a consequence we 
inspected the percentage of samples with cytoplasmatic 
APE1 expression. This informed us that cytoplasmic 
expression of APE1 was present in just 29 % of control 
Table 2  Immunohistochemical expression of 8-OHdG, p53, p21, APE1, IL-6, and IL-8 in: (A) early and (B) late pathology of pregnancy
The values reported refers to median and interquartile range (IQR), and p values refers to Wilcoxon test
(A) Significant differences between: (1) early PE versus early PE and IUGR; (2) early PE versus early HELLP; (3) early PE versus early IUGR; 
(4) early PE versus controls 22–34-week gestation; (5) early PE and IUGR versus early HELLP; (6) early PE and IUGR versus Early IUGR; (7) 
early PE and IUGR versus controls 22–34-week gestation; (8) Early HELLP versus early IUGR; (9) early HELLP versus controls 22–34-week 
gestation; (10) early IUGR versus controls 22–34-week gestation. (NS) = non-significant
(B) Significant differences between: (1) Late PE versus late PE and IUGR; (2) late PE versus late IUGR; (3) late PE versus late SGA; (4) late PE 
versus controls 34–42-week gestation; (5) late PE and IUGR versus Late IUGR; (6) late PE and IUGR versus late SGA; (7) late PE and IUGR 
versus Controls 34–42-week gestation; (8) late IUGR versus late SGA; (9) late IUGR versus controls 34–42-week gestation; (10) late SGA ver-
sus controls 34–42-week gestation. (NS) = non-significant
Early PE Early PE and IUGR Early HELLP Early IUGR Controls 22–34- 
week gestation
p
(A)
Nuclear positivity of 
p21
7.3 (3.5–14.8) 5.1 (2.5–15.2) 6.5 (1.5–11.0) 6.9 (4.6–10.9) 10.0 (5.0–10.0) NS
Nuclear positivity of 
p53
1.4 (0.6–2.5) 1.2 (0.6–1.7) 2.0 (0.4–4.2) 1.2 (0.7–2.0) 1.0 (0.0–1.0) 4, 7, 9, 10
Nuclear H-score of 
APE1
40.0 (20.0–100.0) 25.0 (12.5–67.5) 70.0 (30.0–100.0) 30.0 (10.0–40.0) 30.0 (20.0–32.5) 3,4,9
Cytoplasm intensity of 
APE1
1.0 (1.0–1.0) 1.0 (1.0–1.0) 1.0 (1.0–1.0) 1.0 (1.0–1.0) 0.0 (0.0–1.0) 1, 3, 4, 7, 9, 10
Nuclear H-score 
8-OHdG
140.0 (10.0–160.0) 90.0 (40.0–187.5) 130.0 (10.0–172.5) 90.0 (25.0–155.0) 10.0 (0.0–40.0) 4, 7, 9, 10
Cytoplasm intensity of 
8-OHdG
1.0 (1.0–2.0) 1.5 (1.0–2.0) 1.0 (0.8–1.2) 2.0 (1.0–2.0) 1.0 (1.0–2.0) 8
Cytoplasm intensity 
of IL-6
1.0 (0.0–2.0) 2.0 (1.0–2.0) 1.0 (0.0–2.0) 1.0 (0.0–2.0) 0.0 (0.0–1.0) 4,7,10
Cytoplasm intensity 
of IL-8
1.0 (1.0–1.0) 1.0 (1.0–1.0) 1.0 (1.0–1.0) 1.0 (1.0–2.0) 2.0 (1.2–2.8) 4,7,9,10
Late PE Late PE and IUGR Late IUGR Late SGA Controls 34–42- 
week gestation
p
(B)
Nuclear positivity of 
p21
2.5 (1.6–5.2) 9.0 (3.0–13.3) 5.0 (3.0–12.1) 5.6 (2.9–8.7) 3.1 (1.8–5.9) 1, 2, 3, 7, 9, 10
Nuclear positivity of 
p53
1.5 (0.7–2.0) 2.5 (2.0–3.2) 2.0 (1.3–2.9) 2.2 (0.9–3.0) 1.4 (0.6–2.6) 1, 2, 7, 9
Nuclear H-score of 
APE1
50.0 (27.5–85.0) 75.0 (45.0–130.0) 20.0 (10.0–30.0) 20.0 (10.0–30.0) 20.0 (20.0–70.0) 2, 3, 5, 6, 7, 9
Cytoplasm intensity of 
APE1
1.0 (1.0–1.2) 1.0 (1.0–1.0) 1.0 (1.0–1.0) 1.0 (1.0–1.0) 1.0 (1.0–1.0) 2, 3, 4
Nuclear H-score 
8-OHdG
120.0 (60.0–150.0) 135.0 (90.0–197.5) 80.0 (40.0–160.0) 160.0 (60.0–225.0) 140.0 (60.0–210.0) 9
Cytoplasm intensity of 
8-OHdG
1.0 (1.0–2.0) 1.5 (1.0–2.0) 1.0 (1.0–2.0) 1.0 (1.0–1.0) 1.0 (1.0–2.0) 6, 8, 10
Cytoplasm intensity 
of IL-6
1.0 (0.0–2.0) 2.0 (1.0–2.0) 2.0 (0.2–2.0) 0.0 (0.0–2.0) 1.0 (0.0–2.0) 2
Cytoplasm intensity 
of IL-8
1.0 (1.0–1.0) 1.5 (1.0–2.0) 2.0 (1.0–2.0) 1.0 (1.0–2.0) 2.0 (1.0–2.0) 1, 2, 4, 10
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placentas, which is significantly lower than in cases: 99 % 
in PE; 100 % in HELLP; 85 % in PE with IUGR; and 87 % 
in IUGR. Finally, cytoplasmic expression of APE1 was 
higher in isolated PE than in IUGR (p < 0.05) or in PE 
associated with IUGR (p = 0.067). With regard to HELLP, 
no statistically significant difference was found in compari-
son with IUGR.
Immunohistochemical analysis of 8‑OHdG, p53, 
p21, APE1, IL‑6, and IL‑8 in pregnancy pathology 
after 34‑week gestation and controls
We can make several observations regarding differences 
between cases and controls from the data in Table 2B, where 
we report the univariate analysis of the immunohistochemical 
Table 3  Univariate and multivariate logistic regression analysis of immunohistochemical expression differences in studied proteins between 
controls and cases before the 34-week gestation
The immunohistochemical score of 8-OHdG, p53, p21, APE1, IL-6, and IL-8 higher than the median of the distribution was considered as a 
dependent variable. (*) In multivariate analysis correction for: gestational age at birth, maternal age, nulliparity, and ethnicity
OR (IC 95 %) p OR (IC 95 %) (*) p (*)
Nuclear positivity of p21 No significant differences in comparison with controls
Nuclear positivity of p53
 Controls 22–34-week gestation Reference 1.000 Reference 1.000
 Early PE 37.07 (4.76–288.78) <0.05 29.47 (3.73–232.81) <0.05
 Early PE and IUGR 41.67 (4.44–391.33) <0.05 29.12 (3.02–280.84) <0.05
 Early HELLP 35 (3.49–350.59) <0.05 25.98 (2.55–264.96) <0.05
 Early IUGR 35.71 (4.32–295.06) <0.05 32.97 (3.92–277.43) <0.05
Nuclear H-score of APE1
Controls 22–34-week gestation Reference 1.000 Reference 1.000
 Early PE 3.8 (1.34–10.76) <0.05 3.93 (1.28–12.11) <0.05
 Early PE and IUGR 1.67 (0.4–6.97) 0.484 1.73 (0.38–7.92) 0.477
 Early HELLP 8 (1.59–40.3) <0.05 8.31 (1.54–44.86) <0.05
 Early IUGR 1.29 (0.38–4.31) 0.684 1.31 (0.38–4.52) 0.667
Cytoplasm intensity of APE1
 Controls 22–34-week gestation Reference 1.000 Reference 1.000
 Early PE 160.29 (18.46–1391.75) <0.05 200.25 (20.44–1962.13) <0.05
 Early PE and IUGR 13.36 (2.33–76.48) <0.05 17.25 (2.49–119.41) <0.05
 Early HELLP 12.14 (2.1–70.22) <0.05 15.48 (2.27–105.65) <0.05
 Early IUGR 15.79 (4–62.26) <0.05 18.39 (4.18–80.88) <0.05
Nuclear H-score 8-OHdG
 Controls 22–34-week gestation Reference 1.000 Reference 1.000
 Early PE 14.55 (3.18–66.54) <0.05 11.81 (2.53–55.06) <0.05
 Early PE and IUGR 11 (1.92–63.15) <0.05 7.92 (1.33–47.19) <0.05
 Early HELLP 22 (3.36–144.17) <0.05 16.91 (2.52–113.27) <0.05
 Early IUGR 11 (2.23–54.24) <0.05 10.02 (2–50.36) <0.05
Cytoplasm intensity of 8-OHdG No significant differences in comparison with controls
Cytoplasm intensity of IL-6
 Controls 22–34-week gestation Reference 1.000 Reference 1.000
 Early PE 8.46 (1.78–40.29) <0.05 7.26 (1.4–37.6) <0.05
 Early PE and IUGR 14.67 (2.44–88.13) <0.05 12.16 (1.81–81.51) <0.05
 Early HELLP 5.5 (0.74–40.8) 0.095 4.51 (0.54–37.42) 0.163
 Early IUGR 9.62 (1.64–56.37) <0.05 8.52 (1.39–52.3) <0.05
Cytoplasm intensity of IL-8
 Controls 22–34-week gestation Reference 1.000 Reference 1.000
 Early PE 0.07 (0.02–0.21) <0.05 0.09 (0.03–0.27) <0.05
 Early PE and IUGR 0.07 (0.01–0.34) <0.05 0.09 (0.02–0.49) <0.05
 Early HELLP 0.02 (0–0.33) <0.05 0.02 (0–0.44) <0.05
 Early IUGR 0.19 (0.06–0.58) <0.05 0.21 (0.07–0.66) <0.05
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expression of the studied proteins among different pathol-
ogy groups and controls who delivered after 34-week gesta-
tion. We can see that in comparison with the control group, 
p21 expression was significantly increased in SGA and in 
IUGR (Tables 2B, 4; Fig. 3) and non-significantly increased 
in SGA associated with GH (Supplemental Table 1); p53 
was significantly higher in placentas of patients affected by 
PE associated with IUGR than in controls (Tables 2B, 4); 
nuclear APE1 was significantly higher in isolated PE or PE 
associated with IUGR than in controls (Tables 2B, 4); and 
IL-6 was non-significantly increased in IUGR (Tables 2B, 
4). With regard to GH, the expression of cytoplasmic APE1 
was increased compared to controls (p = 0.056) and IL-8 
decreased (p < 0.05). Cases of GH with SGA presented a 
significantly increased expression of cytoplasmic 8-OHdG 
score, whereas isolated SGA had a significantly decreased 
expression (p < 0.05).
Focussing once again on differences among the pathol-
ogy groups, we observed that p21 was significantly higher 
both in isolated IUGR and IUGR associated with PE than 
in PE alone (p < 0.05) (Fig. 3). A similar pattern was 
observed for p51: Expression of this protein was higher 
in IUGR than in isolated PE. Moreover, placentas affected 
by PE or GH presented a lower expression of p21 in com-
parison with SGA cases. Nuclear APE1 was found to be 
higher in PE than in controls (p < 0.05), and significantly 
increased in both isolated PE and PE associated with IUGR 
than in IUGR or SGA pregnancies (p < 0.05). In PE preg-
nancies, cytoplasmic APE1 was also higher than in SGA 
and IUGR pregnancies (p < 0.05). Cytoplasmic 8-OHdG 
was higher in IUGR cases than in SGA (p < 0.05), while 
nuclear 8-OHdG was lower (p = 0.076). In the placentas of 
patients affected by isolated GH or isolated SGA compared 
to placentas of patients affected by GH in combination with 
SGA, 8-OHdG was increased in the nucleus (p < 0.05) but 
decreased in the cytoplasm (p < 0.05). Finally, IL-6 was 
higher in IUGR than in PE and IL-8 was higher in IUGR 
associated with PE than in PE alone (p < 0.05).
Discussion
In this study, we began by demonstrating that gestational 
age exerted a significant influence on the immunohis-
tochemical expression of 8-OHdG, p21, and APE1 in 
the trophoblast. We then presented results that described 
increased expression of 8-OHdG, p53, APE1, and IL-6 in 
the placentas of PE, HELLP, or IUGR pregnancies when 
compared to controls. In pathology cases both between 22- 
and 34-week gestation and after 34-week gestation, APE1 
expression was higher in the trophoblast of patients with 
hypertensive disorders of pregnancy than in patients with 
Fig. 2  Immunohistochemi-
cal expression in placenta 
from early PE and controls 
of 8-OHdG and APE1. a 
8-OHdG in early PE (original 
magnification ×200; inset, 
×400). b 8-OHdG in controls 
(original magnification ×200; 
inset, ×400). c APE1 in early 
PE (original magnification 
×200; inset, ×400). d APE1 in 
controls (original magnification 
×200; inset, ×400)
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IUGR. Before 34-week gestation, the cytoplasmic expres-
sion of 8-OHdG was increased in the trophoblast of pla-
centas affected by IUGR compared with PE or HELLP. 
After 34-week gestation, we observed increased expres-
sion of p21 in SGA and IUGR cases compared with both 
controls and PE, as well as an increased expression of p53 
in IUGR.
Oxidative stress damage is a known senescence trigger 
and the consequent DNA damage activates the p53-p21 
pathway which applies cell cycle arrest (Burton and Krizh-
anovsky 2014). Furthermore, oxidative stress DNA damage 
is known to induce APE1 for DNA repair thorough the BER 
pathway (Thakur et al. 2015). APE1 itself favors as a redox 
co-activator of transcription factors the production of IL-6 
Table 4  Univariate and multivariate logistic regression analysis of immunohistochemical expression differences in studied proteins between 
controls and cases after 34-week gestation
The immunohistochemical score of 8-OHdG, p53, p21, APE1, IL-6, and IL-8 higher than the median of the distribution was considered as a 
dependent variable. (*) In multivariate analysis correction for: gestational age at birth, maternal age, nulliparity, and ethnicity
OR (IC 95 %) p OR (IC 95 %) (*) p (*)
Nuclear positivity of p21
 Controls >34-week gestation Reference 1.000 Reference 1.000
 Late PE 0.99 (0.41–2.38) 0.983 0.91 (0.37–2.26) 0.840
 Late PE and IUGR 2.69 (0.82–8.83) 0.102 1.99 (0.56–6.99) 0.286
 SGA > 34-week gestation 2.85 (1.29–6.31) <0.05 2.75 (1.21–6.27) <0.05
 Late IUGR 2.72 (1.45–5.12) <0.05 2.72 (1.4–5.28) <0.05
Nuclear positivity of p53
 Controls >34-week gestation Reference 1.000 Reference 1.000
 Late PE 0.56 (0.22–1.44) 0.231 0.57 (0.22–1.51) 0.257
 Late PE and IUGR 4.21 (1.23–14.36) <0.05 4.27 (1.18–15.51) <0.05
 SGA > 34-week gestation 2 (0.92–4.35) 0.080 2.03 (0.91–4.53) 0.084
 Late IUGR 1.68 (0.9–3.14) 0.101 1.71 (0.89–3.28) 0.106
Nuclear H-score of APE1
 Controls >34-week gestation Reference 1.000 Reference 1.000
 Late PE 3.08 (1.1–8.62) <0.05 4.09 (1.41–11.89) <0.05
 Late PE and IUGR 5.14 (1.05–25.04) <0.05 8.59 (1.63–45.25) <0.05
 SGA > 34-week gestation 0.54 (0.22–1.32) 0.175 0.68 (0.27–1.7) 0.409
 Late IUGR 0.48 (0.23–0.97) <0.05 0.56 (0.27–1.17) 0.125
Cytoplasm intensity of APE1 No significant differences in comparison with controls
Nuclear H-score 8-OHdG No significant differences in comparison with controls
Cytoplasm intensity of 8-OHdG
 Controls >34-week gestation Reference 1.000 Reference 1.000
 Late PE 0.81 (0.34–1.93) 0.630 0.69 (0.28–1.70) 0.417
 Late PE and IUGR 1.34 (0.44–4.12) 0.604 0.98 (0.3–3.22) 0.974
 SGA > 34-week gestation 0.42 (0.17–1.00) <0.05 0.36 (0.15–0.89) <0.05
 Late IUGR 1.00 (0.54–1.87) 0.989 0.91 (0.47–1.73) 0.764
Cytoplasm intensity of IL-6
 Controls >34-week gestation Reference 1.000 Reference 1.000
 Late PE 0.51 (0.21–1.28) 0.152 0.57 (0.22–1.5) 0.256
 Late PE and IUGR 1.44 (0.46–4.57) 0.531 1.74 (0.49–6.23) 0.395
 SGA > 34-week gestation 0.67 (0.25–1.79) 0.422 0.76 (0.26–2.17) 0.605
 Late IUGR 1.99 (0.86–4.59) 0.108 2.22 (0.91–5.44) 0.081
Cytoplasm intensity of IL-8
 Controls >34-week gestation Reference 1.000 Reference 1.000
 Late PE 0.1 (0.03–0.36) <0.05 0.14 (0.04–0.5) <0.05
 Late PE and IUGR 0.85 (0.28–2.6) 0.775 1.48 (0.45–4.89) 0.524
 SGA > 34-week gestation 0.44 (0.2–0.99) <0.05 0.58 (0.25–1.33) 0.201
 Late IUGR 0.96 (0.51–1.78) 0.885 1.22 (0.64–2.34) 0.547
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and IL-8 that are part of SASP (Coppé et al. 2008). SASP in 
particular could negatively impact the local microenviron-
ment by autocrine and paracrine effects (Young and Narita 
2009). In line with our expectations, our study demonstrates 
that as gestational age increases, so too does the immunohis-
tochemical expression of 8-OHdG, APE1, and p53, while—
contrary to expectations—p21 significantly decreased 
with an increase in gestational age. However, our data did 
conclude that there was a significant positive correlation 
between p53 and p21 immunohistochemical scores. There-
fore, these aging biomarkers in general seem to increase 
with placental age increase. Furthermore, considering the 
studied pathways in early pregnancy pathology, these bio-
markers had higher immunohistochemical scores (8-OHdG, 
p53, APE1, and IL-6) in comparison with controls (Table 3). 
The only exception was the lower scores found for IL-8 in 
comparison with controls, and for this exception we cur-
rently do not yet have a satisfactory explanation. Looking 
at late pregnancy pathology, placentas from IUGR and SGA 
pregnancies stand out as having higher aging biomarker 
scores than controls (p53, p21, APE1, and IL-6) (Table 4 
and Supplemental Table 1). The fact that we did not detect 
significance when testing for differences between 8-OHdG 
nuclear score in late pregnancy pathology versus controls 
could be attributed to a natural aging of the placenta in con-
trol cases, with the result being that they therefore present a 
similar pattern of DNA oxidation.
In the existing literature, there are several studies about 
the involvement of p21 and p53 in pregnancy pathologies 
related to abnormal placentation. The same can be said for 
APE1. IL-6 and IL-8, on the other hand, have been pri-
marily studied in fluid samples (amniotic fluid or blood). 
In a review article collating findings published up to 2008 
concerning the pathway of apoptosis in the trophoblast and 
its role in pregnancy diseases, there are conflicting results. 
These are in part due to the composition of the studied 
population and in part due to the gestational age at which 
the samples were collected (in most cases, gestational age 
is significantly different between cases and controls) (Hea-
zell et al. 2008). The difference in gestational age between 
cases and controls in particular could lead to biased results 
because, as we found in our study, gestational age signifi-
cantly influences placental protein expression.
It is known that in trophoblast isolated from pregnan-
cies complicated by PE and IUGR there is an increased 
susceptibility to apoptosis (Heazell et al. 2008). These 
observations have informed the hypothesis that in the con-
text of these pregnancy complications, there may be an 
imbalance in the regulation of apoptosis which leads to an 
increased susceptibility to apoptosis itself as pro-apoptotic 
stimuli present themselves (Heazell et al. 2008). However, 
although the existing literature offers plenty of evidence to 
indicate an increased apoptosis in the trophoblast of pla-
centas from PE or IUGR pregnancies, there are few studies 
Fig. 3  Immunohistochemical 
expression in placenta from late 
IUGR and controls of p21 and 
p53. a The p21 in late IUGR 
(original magnification ×200; 
inset, ×400). b The p21 in 
controls (original magnifica-
tion ×200; inset, ×400). c The 
p53 in late IUGR (original 
magnification ×200; inset, 
×400). d The p53 in controls 
(original magnification ×200; 
inset, ×400)
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that investigate changes in the proteins involved in cell 
cycle control.
Regarding the expression of p53 in placentas from 
pathologic pregnancies, IUGR pregnancies have been the 
most widely studied to date. Levy and colleagues and Hea-
zell and colleagues showed an increase of p53 and of the 
cascade pro-apoptotic proteins in IUGR pregnancies com-
pared to controls (Levy et al. 2002; Heazell et al. 2011). 
Contrary to these findings, Jeschke and colleagues evinced 
a reduced expression of p53 in cases of IUGR in relation to 
controls (Jeschke et al. 2006), while Endo and colleagues 
found no difference in the expression of p53 between 
cases and controls (Endo et al. 2005). From our analysis, 
it appears that p53 immunohistochemical expression was 
not significantly affected by gestational age among con-
trols (although when including cases, it was significantly 
increased as gestational age increased), and our results con-
firm that p53 was increased in IUGR compared to controls 
in both groups of pathology between 22- and 34-week ges-
tation and above 34-week gestation. Focusing on this more 
deeply, in the range between 22- and 34-week gestation, 
p53 was increased in all obstetric pathologies likely to be 
of placental origin, while in the over 34-week gestation p53 
was over-expressed only in the placentas of pregnancies 
complicated by IUGR, in comparison both with controls 
and with late PE. It is also noteworthy that Jeschke and col-
leagues did not find differences between PE and controls, 
but did for HELLP compared with controls, where p53 was 
significantly increased in HELLP pregnancies (Jeschke 
et al. 2006). In our study, we confirm a significant increase 
of p53 immunohistochemical expression in placentas from 
pregnancies affected by HELLP, but in addition to this, we 
observed the same significant difference for PE.
We are aware of only one study that addresses the 
expression of p21 in the trophoblast of placentas from 
IUGR pregnancies. This study provides a comparison 
between six placentas from normal pregnancies with a 
39-week term and six placentas from IUGR pregnancies 
with a median of 37-week gestation (Heazell et al. 2011). 
Here, Heazell and colleagues found an increased expres-
sion of p21 in IUGR when compared to controls (Heazell 
et al. 2011). Our own results support these findings, indi-
cating an increased expression of p21 in IUGR (and inci-
dentally also in SGA pregnancies) compared to controls for 
patients who delivered after 34-week gestation. However, 
this difference did not hold for the range of cases, including 
IUGR, who delivered between 22- and 34-week gestation. 
This could be due to the fact that early and late IUGR are 
two different pathologies or simply to the fact that p21 is 
subject to fluctuations over the course of a pregnancy, play-
ing one function in cases where IUGR fetuses are delivered 
before or after 34-week gestation, and another, general role 
in early placental life.
There is likewise not a great deal of the existing litera-
ture concerning 8-OHdG and APE1. In the one study we 
were able to locate, an evaluation of the expression level 
of these two proteins in the trophoblast of pathological 
pregnancies is presented. Here, 11 placentas from full-term 
pregnancies are compared with 10 placentas from preg-
nancies affected by late-onset preeclampsia and 13 pla-
centas from pregnancies affected predominantly by early 
onset preeclampsia associated with IUGR (Fujimaki et al. 
2011). In this context, Fujimaki and colleagues found that 
8-OHdG expression levels are higher in both the catego-
ries of pathological pregnancies but its expression is par-
ticularly pronounced among cases of IUGR (mainly before 
34-week gestation) (Fujimaki et al. 2011). We correspond-
ingly found a higher expression of 8-OHdG in IUGR cases, 
as well as in our other pathologic groups, where delivery 
was between 22- and 34-week gestation, as compared with 
controls. However, comparing IUGR pregnancies with PE 
or HELLP pregnancies, a significantly increased expression 
of 8-OHdG was only observed locally in the cytoplasm. 
With regard to APE1, Fujimaki and colleagues found a 
higher expression of APE1 in placentas from preeclamptic 
pregnancies than in both controls and in PE associated with 
IUGR (Fujimaki et al. 2011). In our study, we too observed 
a significant association between APE1 and hypertensive 
pregnancy disorders. Our finding noted above concerning a 
cytoplasmic staining for 8-OHdG could be explained by the 
localization of 8-OHdG on RNA sites (Tell et al. 2010). In 
a similar vein, we noted cytoplasmic APE1 staining in our 
results. Since APE1 is known to be localized in mitochon-
dria (Barchiesi et al. 2015), the higher levels of specifically 
cytoplasmic APE1 in pathologic pregnancies (especially 
PE) as compared with controls is potentially related to the 
fact that in PE both mitochondria and mitochondrial pro-
teins are more abundant (Jones and Fox 1980; Wang and 
Walsh 1998).
In PE and IUGR pregnancies, both IL-6 and IL-8 have 
been found at increased levels in maternal and fetal flu-
ids (Hahn-Zoric et al. 2002; Sargent et al. 2006; Visentin 
et al. 2014). A previous study went on to demonstrate that 
mRNA levels of IL-6 and IL-8 in placental tissue were 
found to be increased in IUGR/SGA pregnancies when 
compared with controls (Hahn-Zoric et al. 2002). In con-
trast to these data, a recent study concluded that there were 
no significant differences in IL-6 or IL-8 mRNA placental 
tissue levels between IUGR and controls (Amu et al. 2006). 
In our study, we generally found IL-6 placental immuno-
histochemical scores to be higher in cases than in controls, 
and IL-8 scores to be significantly lower.
In this study we hypothesized that placenta from preg-
nancy complications (e.g., PE or IUGR) has an increased 
aging velocity in comparison with controls. Indeed our 
results do show that immunohistochemistry scores of 
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aging biomarkers are generally higher in cases than in 
controls. In addition, increased APE1 levels may be of 
importance. Should future research confirm these find-
ings, APE1 levels could be decreased by diet supplemen-
tations—perhaps to be targeted at high-risk pregnancies 
(e.g., Catechins isolated from the leaves of green tea asso-
ciated with Curcumin) (Thakur et al. 2014). SASP may 
also exacerbate the effect of placental aging by establish-
ing a vicious mechanism due to cytokines such IL-6. Thus, 
the suppression of SASP could also be a possible thera-
peutic target (Hayakawa et al. 2015). Furthermore, aspirin 
treatment could decrease trophoblast levels of p53 (Costa 
et al. 2013).
While this study is limited in terms of its retrospec-
tive design and restriction only to the immunohistochemi-
cal expression of the studied factors, it benefits from the 
wide range of pathology included in the tissue micro-array, 
which allowed us to assess several pathologies in a stand-
ardized manner. The immunohistochemical expression 
analysis alone is limiting the possibility of comparing the 
expression of two different proteins between them and fur-
ther studies with quantitative techniques, even on small 
sample size, are needed to confirm our data. Moreover, by 
including controls stratified for gestational age, we have 
presented a set of data that are rare to find in other pub-
lished studies. Despite our efforts, particularly in early pla-
cental pathology still exists a gestational age gap between 
cases and controls that was found to be irrelevant after mul-
tivariate logistic regression analysis.
In summary, we found that placentas from pathological 
pregnancies have an altered expression of 8-OHdG, p53, 
p21, APE1, IL-6, and IL-8. The alterations of intracellular 
pathways involving these elements can be the cause or the 
consequence of placental dysfunction in the various dis-
eases considered. Further analysis of the role of p53, p21, 
APE1, IL-6, and IL-8 in the field of obstetric pathology is 
needed to understand whether a targeted therapy to their 
rebalancing may have clinical significance.
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